pdr001,trametinib,dabrafenib
novartis
['combi-i', 'melanoma']
analyses from the combi-i trial evaluating pd-1, braf and mek inhibition in patients with metastatic #melanoma demonstrate high response rates and uncover molecular correlates of long-term treatment benefit. trial led by #aacr23 speaker reinhard dummer 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.